General
Preferred name
FLUTICASONE PROPIONATE
Synonyms
CCI-187881 ()
Flixonase ()
Advair-fluticasone propionate ()
Fluticasone (propionate) ()
Propionate ()
FLUTICASONE ()
Seretide 50 ()
Flixotide ()
Seretide 500 ()
NSC-759889 ()
Fluticasone propionate ()
Sereflo ()
Flutiform ()
Xhance ()
Aerivio Spiromax ()
Flonase allergy relief ()
Flovent Diskus 250 ()
R01AD08 ()
Seretide 100 ()
Fluticaps ()
AirFluSal Forspiro ()
Armonair digihaler ()
Opn-375 ()
Flonase ()
Flovent Hfa ()
PF-00241939 ()
Sirdupla ()
Flovent ()
Flovent Diskus 50 ()
Seretide 250 ()
Nasofan ()
Pirinase ()
Flovent Diskus 100 ()
CCI 18781 ()
Armonair respiclick ()
CCI-18781 ()
Cutivate ()
Optinose ()
Fluticasone-17-propionate ()
Seretide 125 ()
CCI18781 ()
Fluticasone propionate ()
P&D ID
PD002989
CAS
80474-14-2
Tags
probe
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
1990
Drug Status
approved
Drug indication
Anti-Inflammatory
Asthma
Max Phase
Phase 4
Probe info
Probe type
calculated probe
Probe sources
Probe Miner (suitable probes)
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Systemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats[F4358][FDA Label]. Fluticasone propionate as a topical formulation is also associated with vasoconstriction in the skin[F4355,A177118].
HALF-LIFE 7.8 hours for intravenous fluticasone propionate[F4358][FDA Label]. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation[A7490].
MOA Fluticasone propionate works through an unknown mechanism to affect the action of various cell types and mediators of inflammation[F4358]. Fluticasone propionate activates glucocorticoid receptors and inhibits lung eosinophilia in rats[F4358,F4355].
INDICATION Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. A fluticasone propionate nasal spray is indicated for managing nonallergic rhinitis[F4358].
ROE Fluticasone propionate is mainly eliminated in the feces with <5% eliminated in the urine[F4358,A176918][FDA Label].
DESCPRITION A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.
METABOLISM Fluticasone propionate is cleared from hepatic metabolism by cytochrome P450 3A4[F4358,A177121][FDA Label]. Fluticasone propionate is hydrolysed at the FIVE-S-fluoromethyl carbothioate group, forming an inactive metabolite[F4355,A177118][FDA Label].
ABSORPTION Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%[F4358][FDA Label]. Intranasal exposure results in the majority of the dose being swallowed[A177118]. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease[F4355]. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%[A7490].
TOXICITY Fluticasone propionate's use in specific populations has not been well studied[F4358]. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies[F4358][FDA Label]. Subcutaneous fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not[F4355][FDA Label]. Generally, there are no reported adverse effects with fluticasone in pregnancy[A177127]. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects[F4355,A7488]. Pediatric patients treated with fluticasone propionate ointment experienced adrenal suppression[F4355]. Geriatric patients treated with fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects[F4355]. There is no difference in the clearance of fluticasone propionate across genders or race[FDA Label]. Patients with hepatic impairment should be closely monitored due to the elimination mechanism[FDA Label][A176918].
DESCRIPTION Fluticasone propionate is a corticosteroid, high affinity and selective glucocorticoid receptor agonist. (GtoPdb)
DESCRIPTION Selective high affinity glucocorticoid receptor agonist (Tocriscreen Plus)
DESCRIPTION Broad spectrum steroid receptor ligand. Antagonizes FXR and displays hypolipidemic activity (Tocris Bioactive Compound Library)
DESCRIPTION Selective high affinity glucocorticoid agonist (Tocriscreen Total)
Cell lines
1
Organisms
0
Compound Sets
30
AdooQ Bioactive Compound Library
A11860
ChEMBL Approved Drugs
CHEMBL1473
ChEMBL Drugs
CHEMBL1473
Concise Guide to Pharmacology 2017/18
7080
Concise Guide to Pharmacology 2019/20
7080
Concise Guide to Pharmacology 2021/22
7080
Concise Guide to Pharmacology 2023/24
7080
Drug Repurposing Hub
DrugBank
DB00588
DrugBank Approved Drugs
DB00588
DrugCentral
1225
DrugCentral Approved Drugs
1225
DrugMAP
DMRWLB2
DrugMAP Approved Drugs
DMRWLB2
EU-OPENSCREEN Bioactive Compound Library
EOS101465
Guide to Pharmacology
7080
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1473
MedChem Express Bioactive Compound Library
HY-B0154
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
O2GMZ0LF5W
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
Probe Miner (suitable probes)
P04150/562665
ReFrame library
Selleckchem Bioactive Compound Library
fluticasone-propionate-Flonase-Veramyst
TargetMol Bioactive Compound Library
T0188
Tocris Bioactive Compound Library
2007
Tocriscreen Plus
2007
Tocriscreen Total
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
500.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
0
cLogP
4.43
TPSA
80.67
Fraction CSP3
0.72
Chiral centers
9.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Nuclear Receptors
Pathway
Endocrinology/Hormones
Metabolism
Anti-infection
Immunology/Inflammation
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Target
ER
Mineralocorticoid Receptor
Glucocorticoid Receptor
Cytosolic PLA2
NR3C1, NR3C2, PGR, PLA2G4A
Endogenous Metabolite
Enterovirus
Primary Target
Glucocorticoid Receptors
MOA
Agonist
Glucocorticoid Receptor agonist
Indication
corticosteroid-responsive dermatoses
Biosynthetic Origin
Terpenoid (Steroid)
Therapeutic Indication
Antiinflammatory
Source data